AlloVir, Inc. (NASDAQ:ALVR) Insider Sells $12,281.77 in Stock

AlloVir, Inc. (NASDAQ:ALVRGet Free Report) insider Vikas Sinha sold 18,331 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $0.67, for a total value of $12,281.77. Following the completion of the sale, the insider now owns 1,145,252 shares in the company, valued at approximately $767,318.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Vikas Sinha also recently made the following trade(s):

  • On Tuesday, January 23rd, Vikas Sinha sold 3,205 shares of AlloVir stock. The shares were sold at an average price of $0.67, for a total value of $2,147.35.
  • On Thursday, January 4th, Vikas Sinha sold 961 shares of AlloVir stock. The shares were sold at an average price of $0.64, for a total value of $615.04.
  • On Friday, November 17th, Vikas Sinha sold 2,490 shares of AlloVir stock. The shares were sold at an average price of $1.63, for a total value of $4,058.70.

AlloVir Stock Performance

NASDAQ:ALVR opened at $0.67 on Friday. The stock has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $1.89. The stock has a market cap of $76.80 million, a P/E ratio of -0.40 and a beta of 0.84. AlloVir, Inc. has a 1 year low of $0.62 and a 1 year high of $7.24.

Analyst Ratings Changes

ALVR has been the subject of several analyst reports. JPMorgan Chase & Co. cut AlloVir from an “overweight” rating to an “underweight” rating in a research note on Friday, December 22nd. Bank of America cut AlloVir from a “buy” rating to an “underperform” rating in a research note on Tuesday, December 26th. Piper Sandler cut AlloVir from an “overweight” rating to a “neutral” rating in a research note on Friday, December 22nd. SVB Leerink cut AlloVir from an “outperform” rating to a “market perform” rating in a research note on Friday, December 22nd. Finally, Leerink Partnrs cut AlloVir from an “outperform” rating to a “market perform” rating in a research note on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $18.67.

Get Our Latest Report on ALVR

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALVR. Swiss National Bank boosted its position in shares of AlloVir by 7.5% during the 1st quarter. Swiss National Bank now owns 84,800 shares of the company’s stock worth $572,000 after acquiring an additional 5,900 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of AlloVir by 27.7% during the 1st quarter. JPMorgan Chase & Co. now owns 763,908 shares of the company’s stock worth $5,157,000 after acquiring an additional 165,711 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of AlloVir by 51.5% during the 1st quarter. MetLife Investment Management LLC now owns 18,052 shares of the company’s stock worth $122,000 after acquiring an additional 6,136 shares in the last quarter. BlackRock Inc. boosted its position in shares of AlloVir by 2.9% in the 1st quarter. BlackRock Inc. now owns 2,230,919 shares of the company’s stock valued at $15,059,000 after purchasing an additional 62,747 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in AlloVir by 43.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 70,387 shares of the company’s stock worth $476,000 after buying an additional 21,337 shares during the last quarter. 47.41% of the stock is owned by institutional investors and hedge funds.

About AlloVir

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Further Reading

Insider Buying and Selling by Quarter for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.